Lupin, Dr Reddy's Lab, Coal India, Tata Motors DVR hit 52-week lows
Ajanta Pharma and PI Industries are others from the Nifty 500 index too hit 52-week low on NSE.
 "Lupin, Dr Reddy's Lab, Coal India, Tata Motors DVR hit 52-week lows")
premium
Lupin, Dr Reddy’s Laboratories, Coal India and Tata Motors DVR (Differential Voting Rights) from the Nifty50 index hit their respective 52-week lows, down up to 4% on the National Stock Exchange (NSE).
Coal India, the biggest loser among Nifty 50 index, was down 4% to Rs 242, extending its previous day’s 1% decline on BSE.
The company produced 155.4 million tonnes (mt) of coal in April-July of 2017- 18, missing the target by 12.6 mt. The production goal for April-July was 168 mt, Coal India said in a filing to the BSE on Tuesday.
Lupin too slipped 4% to Rs 996, extending its 12% decline in past 10 trading days. The pharmaceutical company had posted a bad set of numbers for the quarter ended June (Q1FY18). The consolidated net profit more than halved to Rs 358 crore from Rs 882 crore in year ago quarter.
On operating front, the EBITDA (earnings before interest, taxation, depreciation and amortization) margins came in at 18.5% against 27.4% in 1QFY2017, mainly on back of lower than expected sales during the quarter and dip in the gross margins.
Commenting on the results, Nilesh Gupta, Managing Director, Lupin, said “Our Q1, FY2018 results have been below our own expectations on count of higher than anticipated price erosion in select products like Glumetza, disruption on count of GST implementation in India and appreciation in the rupee.”
Ajanta Pharma and PI Industries are others from the Nifty 500 index too hit 52-week low on NSE.
Coal India, the biggest loser among Nifty 50 index, was down 4% to Rs 242, extending its previous day’s 1% decline on BSE.
The company produced 155.4 million tonnes (mt) of coal in April-July of 2017- 18, missing the target by 12.6 mt. The production goal for April-July was 168 mt, Coal India said in a filing to the BSE on Tuesday.
Lupin too slipped 4% to Rs 996, extending its 12% decline in past 10 trading days. The pharmaceutical company had posted a bad set of numbers for the quarter ended June (Q1FY18). The consolidated net profit more than halved to Rs 358 crore from Rs 882 crore in year ago quarter.
On operating front, the EBITDA (earnings before interest, taxation, depreciation and amortization) margins came in at 18.5% against 27.4% in 1QFY2017, mainly on back of lower than expected sales during the quarter and dip in the gross margins.
Commenting on the results, Nilesh Gupta, Managing Director, Lupin, said “Our Q1, FY2018 results have been below our own expectations on count of higher than anticipated price erosion in select products like Glumetza, disruption on count of GST implementation in India and appreciation in the rupee.”
Ajanta Pharma and PI Industries are others from the Nifty 500 index too hit 52-week low on NSE.
| COMPANY | LATEST | 52 WK LOW | PREV LOW | PREV DATE |
| AJANTA PHARMA | 1341.85 | 1335.10 | 1370.05 | 02-Aug-17 |
| COAL INDIA | 241.80 | 241.20 | 242.60 | 03-Jul-17 |
| DR REDDY'S LABS | 2341.85 | 2337.00 | 2369.80 | 01-Aug-17 |
| LUPIN | 1003.05 | 995.25 | 1016.10 | 01-Aug-17 |
| P I INDS. | 723.40 | 721.50 | 726.65 | 09-Nov-16 |
| RATTANINDIA POW. | 6.30 | 6.20 | 6.30 | 27-Dec-16 |
| TATA MOTORS-DVR | 253.75 | 253.15 | 257.45 | 05-May-17 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%